CN105848687B - 放射性示踪剂组合物和方法 - Google Patents

放射性示踪剂组合物和方法 Download PDF

Info

Publication number
CN105848687B
CN105848687B CN201480069324.9A CN201480069324A CN105848687B CN 105848687 B CN105848687 B CN 105848687B CN 201480069324 A CN201480069324 A CN 201480069324A CN 105848687 B CN105848687 B CN 105848687B
Authority
CN
China
Prior art keywords
radiotracer
solution
formula
fluorobenzaldehyde
reversed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480069324.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105848687A (zh
Inventor
T.恩格尔
G.S.格特福尔德森
A.R.迈耶尔
I.A.卡恩
R.J.奈尔内
G.麦克罗比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN105848687A publication Critical patent/CN105848687A/zh
Application granted granted Critical
Publication of CN105848687B publication Critical patent/CN105848687B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201480069324.9A 2013-12-18 2014-12-18 放射性示踪剂组合物和方法 Active CN105848687B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322456.3A GB201322456D0 (en) 2013-12-18 2013-12-18 Radiotracer compositions and methods
GB1322456.3 2013-12-18
PCT/EP2014/078609 WO2015091882A1 (en) 2013-12-18 2014-12-18 Radiotracer compositions and methods

Publications (2)

Publication Number Publication Date
CN105848687A CN105848687A (zh) 2016-08-10
CN105848687B true CN105848687B (zh) 2020-06-09

Family

ID=50071052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480069324.9A Active CN105848687B (zh) 2013-12-18 2014-12-18 放射性示踪剂组合物和方法

Country Status (6)

Country Link
US (3) US10300156B2 (https=)
EP (1) EP3082879A1 (https=)
JP (2) JP6824738B2 (https=)
CN (1) CN105848687B (https=)
GB (1) GB201322456D0 (https=)
WO (1) WO2015091882A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN108218651B (zh) * 2018-02-27 2023-11-03 首都医科大学宣武医院 用于制备放射性药物的一次性辅助装置及方法
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction
GB201915206D0 (en) * 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
GB201919016D0 (en) * 2019-12-20 2020-02-05 Ge Healthcare Ltd Apparatus and method for solid phase extraction
EP4087592A1 (en) * 2020-01-10 2022-11-16 Real Isolates, LLC Methods for obtaining compounds from a plant or fungus material, respective compositions, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
WO2012087725A1 (en) * 2010-12-21 2012-06-28 Ge Healthcare Limited Use of aniline iν the radiostabilization of oxime ligation
CN103153350A (zh) * 2010-08-18 2013-06-12 通用电气健康护理有限公司 肽放射性示踪剂组合物
WO2013174909A1 (en) * 2012-05-24 2013-11-28 Ge Healthcare Limited Purification of [18f] - fluciclatide

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
GB0105224D0 (en) 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
EP1516185A4 (en) 2001-12-27 2007-06-20 Van Andel Res Inst Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
US7018614B2 (en) 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
JP2006505610A (ja) * 2002-11-05 2006-02-16 イヨン ベアム アプリカスィヨン エッス．アー． １８−ｆ標識放射性製剤の安定化
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
EP1952826A4 (en) 2005-10-24 2011-05-18 Fujifilm Ri Pharma Co Ltd DIAGNOSTIC AGENT AND THERAPEUTIC AGENT FOR DISEASES RELATED TO THE HEPATOCYTE GROWTH FACTOR RECEPTOR
US20100068150A1 (en) 2006-07-07 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Selective Caspase Inhibitors
GB0615211D0 (en) 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
US8247534B2 (en) 2006-12-13 2012-08-21 Ge Healthcare As Synthesis of radiofluorinated peptide using microwave activation technology
JP2010520229A (ja) 2007-03-01 2010-06-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 放射性弗素化方法
ATE551073T1 (de) 2007-05-16 2012-04-15 Ge Healthcare As Markierte hgf-bindende peptide für bildgebung
GB0718957D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0716897D0 (en) 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
JP5399422B2 (ja) * 2008-02-28 2014-01-29 ジーイー・ヘルスケア・リミテッド 市販の安価な化学薬品からのｐｅｇ−６成分の合成
US8435454B2 (en) * 2009-07-09 2013-05-07 Siemens Medical Solutions Usa, Inc. Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
GB201020314D0 (en) 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
CA2819347A1 (en) 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method
CN107753962A (zh) 2010-12-09 2018-03-06 通用电气健康护理有限公司 放射性示踪剂组合物
RU2013128360A (ru) 2010-12-22 2015-01-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Her2-связывающие белки, меченые 18f-содержащим кремнийорганическим соединением
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
GB201202420D0 (en) * 2012-02-13 2012-03-28 Ge Healthcare Ltd Radiotracer compositions
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322451D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274623A1 (en) * 2008-01-30 2009-11-05 General Electric Company In vivo imaging agents for met receptor tyrosine kinase
CN103153350A (zh) * 2010-08-18 2013-06-12 通用电气健康护理有限公司 肽放射性示踪剂组合物
WO2012087725A1 (en) * 2010-12-21 2012-06-28 Ge Healthcare Limited Use of aniline iν the radiostabilization of oxime ligation
WO2013174909A1 (en) * 2012-05-24 2013-11-28 Ge Healthcare Limited Purification of [18f] - fluciclatide

Also Published As

Publication number Publication date
US20190275182A1 (en) 2019-09-12
EP3082879A1 (en) 2016-10-26
US20220202965A1 (en) 2022-06-30
US10300156B2 (en) 2019-05-28
JP6824738B2 (ja) 2021-02-03
US20160303263A1 (en) 2016-10-20
US11311636B2 (en) 2022-04-26
GB201322456D0 (en) 2014-02-05
JP2019206533A (ja) 2019-12-05
CN105848687A (zh) 2016-08-10
WO2015091882A1 (en) 2015-06-25
JP2017502946A (ja) 2017-01-26

Similar Documents

Publication Publication Date Title
CN105848687B (zh) 放射性示踪剂组合物和方法
CN103153350B (zh) 肽放射性示踪剂组合物
US20210330824A1 (en) Purification method and compositions
JP2014505021A (ja) アポトーシス用ｐｅｔイメージング剤
US20150139902A1 (en) Purification of [18f] - fluciclatide
CN105452202B (zh) 放射性标记方法
HK1226050A1 (en) Purification method and compositions
HK1186119A (en) Peptide radiotracer compositions
HK1186119B (en) Peptide radiotracer compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant